Skip to search formSkip to main contentSkip to account menu

0.8 ML Fondaparinux sodium 12.5 MG/ML Prefilled Syringe

Known as: FONDAPARINUX SODIUM 10 mg in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [Fondaparinux Sodium], FONDAPARINUX NA 10MG/0.8ML INJ,SYRINGE,0.8ML [VA Product], FONDAPARINUX 10MG/0.8ML INJ SYR 0.8ML 
National Institutes of Health

Related topics

Related topics

17 relations

Broader (1)

Anticoagulants
Bacterial EndocarditisDrug AllergyEnzyme Activators [MoA]Fondaparinux sodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery
BackgroundPharmacological thromboprophylaxis after colorectal cancer (CRC) surgery is internationally recommended for venous… 
2018
2018
Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time‐to‐event analysis
Increased exposure to fondaparinux, as observed in patients with renal impairment, may increase bleeding risk. This study aims to… 
2017
2017
Anwendung von Fondaparinux zur Prophylaxe und Therapie von thrombembolischen Ereignissen während der Schwangerschaft bei Unverträglichkeit von niedermolekularen Heparinen
2017
2017
Fondaparinux and Atrial Fibrillation
2013
2013
Anti‐PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis
Anti‐PF4/heparin antibodies are frequently generated after coronary artery bypass grafting (CABG) surgery, with platelet… 
2012
2012
Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO‐TEP registry
Summary.  Background:  Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients undergoing major orthopedic… 
2008
2008
Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles
Antikoagulanzien auf der Basis von Glykosaminoglykanen (GAG) sind seit Jahrzehnten dominierend in der Therapie und Prophylaxe… 
2007
2007
Faktor-Xa-Inhibition in der interventionellen Kardiologie
Zusammenfassung Eine zwei-oder dreifache antithrombozytäre Therapie kombiniert mit einer systemischen Antikoagulation, wie in der… 
2003
2003
Fondaparinux verglichen mit Enoxaparin in der Prävention venöser thromboembolischer Ereignisse nach chirurgischer Versorgung von Hüftfrakturen
2001
2001
Produktprofil von Pentasaccharid (Fondaparinux-Natrium)
Zusammenfassung Mit dem Pentasaccharid (INN: Fondaparinux) wird demnächst der erste Vertreter einer neuen Substanzklasse von… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)